{
  "abstract": "Cave and Harnden are right that passive pharmacovigilance is no longer adequate for modern medicines regulation.1 The burden of adverse drug reactions makes this a patient safety problem, not merely a data management inconvenience.2 The unresolved question is how the proposed UK Health Data Research Service will convert faster access to data into earlier regulatory action.",
  "authors": [
    {
      "affiliations": [
        "Department of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China"
      ],
      "name": "Biao Nie"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China"
      ],
      "name": "Jinghong Liu"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong Province, China"
      ],
      "name": "Cun Li"
    }
  ],
  "title": "Proactive pharmacovigilance needs predefined action rules",
  "uid": "c25155b9-fc00-5f12-84bd-3ed9adbbade2"
}